Carcinoma in situ of larynx

CD2_INSITU_LARYNX

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions not C3_LARYNX	519637
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D02.0& Hospital discharge: ICD-9 — 2310 Cause of death: ICD-10 — D02.0& Cause of death: ICD-9 — 2310 Cancer registry: Topography ICD-O-3 — C32 Cancer registry: Morphology ICD-O-3 — ANY Cancer registry: Behaviour codes — 2 3 out of 7 registries used, show all original rules.	58
4. Check minimum number of events None	58
5. Include endpoints None	58
6. Filter based on genotype QC (FinnGen only)	58

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF9
Parent code in ICD-10: D02
Name in latin: Carcinoma in situ bronchi

NAME	CD2_INSITU_LARYNX
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS	!C3_LARYNX
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D020
HD_ICD_9	2310
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D020
COD_ICD_9	2310
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO	C32
CANC_TOPO_EXCL
CANC_MORPH	ANY
CANC_MORPH_EXCL
CANC_BEHAV	2

Similar endpoints

↥

List of similar endpoints to Carcinoma in situ of larynx based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Carcinoma in situ of larynx

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	58	11	47
Unadjusted period prevalence (%)	0.02	0.00	0.02
Median age at first event (years)	64.56	38.69	70.62

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
56: Matched controls
558

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

DQB10

NOMESCO Finland

Endoscopic excision of lesion of larynx

580.4

32.3

D14.1

ICD-10 Finland

Benign neoplasm: Larynx

+∞

26.1

C32.0

ICD-10 Finland

Malignant neoplasm: Glottis

352.1

23.5

UDQ12

NOMESCO Finland

Flexible laryngoscopy

38.6

23.4

DQA10

NOMESCO Finland

Biopsy of larynx

+∞

22.4

8070/2-C32.0

ICD-O-3

Squamous cell carcinoma in situ, NOS, of glottis

+∞

18.8

D02.0

ICD-10 Finland

Carcinoma in situ: Larynx

258.6

18.7

D38.0

ICD-10 Finland

Neoplasm of uncertain or unknown behaviour: Larynx

+∞

17.6

C320, 8077, 2

ICD-O-3

+∞

15.3

J37.0

ICD-10 Finland

Chronic laryngitis

39.6

13.9

J38.3

ICD-10 Finland

Other diseases of vocal cords

60.9

12.5

ZXC10

NOMESCO Finland

Use of laser

31.1

12.4

UDQ22

NOMESCO Finland

Microlaryngoscopy

149.5

11.9

2310A

ICD-9 Finland

Carcinoma in situ of respiratory system, Larynx

+∞

7.4

WX404

NOMESCO Finland

Intravenous generell anesthesy

5.8

7.1

EP1AE

NOMESCO Finland

Neck ultrasound examination

10.9

7.0

C32.9

ICD-10 Finland

Malignant neoplasm: Larynx, unspecified

78.4

6.6

WX734

NOMESCO Finland

JET-ventilation

+∞

6.4

8070/2-C32.9

ICD-O-3

Squamous cell carcinoma in situ, NOS, of larynx, NOS

+∞

6.4

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40768804) Tissue Pathology biopsy report

168

3.24

4.61

4.0

2.1

—

(3013512) EKG study

143

2.85

3.70

7.4

5.1

—

(3042936) Bacteria identified in Isolate by Culture

3.30

3.59

1.9

—

(3032080) INR in Blood by Coagulation assay

215

2.78

3.46

11.8

9.2

1.3

inr

0.02

(3037467) Urinalysis macro (dipstick) panel - Urine

297

2.73

2.86

5.1

4.2

—

(3019225) pH of Specimen

3.26

2.85

2.7

5.5

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

212

2.29

2.42

5.8

4.5

76.1

43.3

ng/l

0.42

169

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

196

2.25

2.34

5.0

4.1

—

(4035726)

2.92

2.25

1.7

1.3

—

(3023368) Bacteria identified in Blood by Culture

156

2.21

2.20

5.4

4.9

—

(3007853) Bacteria identified in Skin by Aerobe culture

2.65

2.16

1.8

1.9

—

(3027945) Reticulocytes/100 erythrocytes in Blood

2.57

2.15

2.4

2.5

1.6

1.8

0.43

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

3.04

2.03

1.6

1.3

—

(3044640) Blood type and Crossmatch panel - Blood

144

2.14

2.00

3.2

2.6

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

401

2.43

1.82

25.0

17.8

73.7

74.0

ml/min/173m2

0.04

328

(3000492) Spirometry study

2.93

1.80

2.1

1.7

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

194

1.99

1.76

2.4

2.5

—

(40761511) CBC panel - Blood by Automated count

442

2.70

1.69

27.0

16.7

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

3.54

1.55

1.4

2.9

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

449

2.53

1.53

31.5

22.1

92.1

88.2

umol/l

0.17

449

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

3.32

1.47

1.2

1.7

—

(40761536) Microorganisms panel - Urine sediment

2.35

1.41

4.6

4.0

—

(3022313) Gas panel - Capillary blood

2.67

1.34

3.3

4.0

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.23

1.34

1.9

3.2

—

(3020630) Protein [Mass/volume] in Serum or Plasma

2.26

1.31

1.9

4.4

68.2

66.1

g/l

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

2.56

1.28

2.8

4.1

27.6

24.8

mmol/l

—

(42870588) Differential panel, method unspecified - Blood

149

1.77

1.19

6.3

5.3

—

(3012095) Magnesium [Moles/volume] in Serum or Plasma

1.90

1.18

4.7

4.2

0.8

mmol/l

0.23

(3004119) Hemoglobin [Mass/volume] in Venous blood

2.51

1.17

2.6

3.5

134.9

124.6

g/l

—

(3020682) Albumin/Creatinine [Ratio] in Urine

150

1.75

1.16

4.5

4.0

2.4

14.0

mg/mmol

2.37

(3044889) 12 lead EKG panel

314

1.74

1.12

4.5

4.6

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

2.13

1.10

1.8

2.9

25.7

7.9

umol/l

—

(3002032) Base excess in Venous blood by calculation

2.03

1.06

3.3

4.4

3.0

2.5

mmol/l

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

277

1.66

1.04

5.7

5.4

7.8

6.9

mmol/l

0.69

258

(3000494) Fungus identified in Specimen by Culture

1.90

1.00

1.2

1.6

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.99

0.99

1.9

1.8

—

(3012516) Albumin [Mass/volume] in Urine

139

1.67

0.97

3.1

3.2

60.4

96.4

mg/l

0.29

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

185

1.62

0.95

3.9

3.6

—

(40760892) CBC W Ordered Manual Differential panel - Blood

1.81

0.94

4.1

7.3

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

195

1.60

0.93

2.2

2.1

98.9

88.1

pmol/l

0.96

118

(3041096) Erythrocytes [Presence] in Urine by Automated

114

1.69

0.93

3.9

3.7

—

(3009542) Hematocrit [Volume Fraction] of Blood

344

1.65

0.92

21.8

18.4

39.3

0.01

218

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.78

0.91

2.8

2.1

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.97

0.84

1.0

1.5

—

(3013707) Erythrocyte sedimentation rate by Westergren method

327

1.59

0.84

4.8

4.2

15.7

14.0

mm/h

0.20

291

(3002256) Pathology report gross observation

1.79

0.79

1.4

1.2

—

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

2.18

0.76

2.6

2.9

0.7

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.73

0.75

7.4

3.7

—

(3000330) Specific gravity of Urine by Test strip

2.09

0.74

2.0

5.8

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

2.09

0.74

2.6

2.9

2.0

1.1

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.65

0.74

2.2

2.0

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

302

1.51

0.73

6.5

5.3

1.6

2.1

ug/l

0.90

257

(3028286) Albumin [Mass/volume] in Serum or Plasma by Electrophoresis

2.01

0.72

2.4

3.1

43.1

37.7

g/l

—

(3021601) Nitrite [Presence] in Urine by Test strip

224

1.48

0.71

3.6

5.5

0.0

estimate

—

(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.86

0.68

2.4

3.0

2.6

3.1

g/l

—

(3035350) Ketones [Presence] in Urine by Test strip

226

1.46

0.67

2.9

4.2

0.0

estimate

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

1.79

0.65

2.4

2.0

—

(3009261) Glucose [Presence] in Urine by Test strip

227

1.45

0.65

3.0

4.2

0.0

estimate

—

(3003458) Phosphate [Moles/volume] in Serum or Plasma

1.65

0.64

2.8

7.1

1.1

1.0

mmol/l

0.22

(3043747) Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.73

0.63

2.4

2.9

3.7

3.5

g/l

—

(3005229) Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.73

0.63

2.4

2.9

6.8

7.2

g/l

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.73

0.63

2.4

2.9

—

(3003031) Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma

1.73

0.63

1.0

1.7

1.5

2.5

—

(4034850)

0.00

0.60

0.0

18.7

—

(3019060) Gas panel - Arterial blood

1.59

0.50

2.3

4.7

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

104

1.46

0.49

3.9

2.6

—

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

170

0.70

0.47

3.2

0.8

0.7

ug/l

—

126

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

1.44

0.44

1.6

2.7

4.3

5.8

ug/l

—

(36304419) Bacteria [Presence] in Urine

134

1.38

0.43

5.2

3.0

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.00

0.41

0.0

1.1

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

239

0.75

0.41

6.8

4.7

23.1

21.5

—

125

(3020961) Endomysium IgA Ab [Titer] in Serum

0.00

0.40

0.0

1.1

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.47

0.40

1.0

1.4

—

(3026008) Bacteria identified in Urine by Culture

137

1.34

0.38

2.9

3.4

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

175

1.31

0.37

3.5

4.4

—

(1761868) Lipid panel - Serum or Plasma

128

1.35

0.37

4.1

3.3

—

(3029937) Albumin [Presence] in Urine by Test strip

138

1.33

0.36

3.5

4.2

0.0

estimate

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

117

0.73

0.31

1.6

4.2

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

122

1.31

0.31

2.1

1.9

2.5

3.2

mg/l

0.75

107

(3018418) pH of Serum or Plasma

133

1.28

0.28

6.0

5.5

7.4

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.24

0.22

1.0

1.3

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.6

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.21

0.0

1.6

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

0.00

0.21

0.0

1.0

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.2

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.00

0.21

0.0

1.6

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

157

1.21

0.21

3.5

2.2

303.0

168.2

u/l

0.50

149

(3002385) Erythrocyte distribution width [Ratio]

342

1.14

0.12

31.1

22.0

14.1

14.0

0.32

335

(3000991) Gas panel - Venous blood

1.07

0.10

3.0

9.0

—

(40761535) Cells panel - Urine sediment

1.05

0.09

1.2

3.9

—

(40768797) Stomach Pathology biopsy report

0.80

0.09

1.8

1.2

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

1.05

0.08

1.9

2.9

2.3

2.2

g/l

—

(3003694) ABO and Rh group [Type] in Blood

101

1.11

0.04

1.9

1.4

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

178

0.94

0.02

3.6

2.7

193.2

166.1

ug/l

0.17

159

(40758558) Short blood count panel - Blood

113

1.08

0.02

9.3

7.6

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

0.00

0.0

1.2

—

(3004616) Nuclear Ab [Presence] in Serum

0.00

0.0

1.2

—

(3052649) Adenosine deaminase [Enzymatic activity/volume] in Serum or Plasma

0.00

0.0

2.0

—

15.7

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.0

1.2

—

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

0.93

0.00

3.0

4.8

12.3

68.2

ug/l

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

(3018387) Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum

0.00

0.0

1.3

—

(3020491) Glucose [Moles/volume] in Blood

0.00

0.0

2.2

—

6.6

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.0

1.2

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.0

1.0

—

(3044290) Cell count panel - Cerebral spinal fluid

0.00

0.0

1.0

—

(21494434) Karyotype in Bone marrow

0.00

0.0

1.0

—

(3016879) Cocaine [Presence] in Urine

0.00

0.0

1.0

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.2

—

(3012447) Hantavirus puumala IgG Ab [Titer] in Serum

0.00

0.0

1.0

—

(3038026) Centromere Ab [Units/volume] in Serum

0.00

0.0

1.2

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.4

—

(3036428) Adenosine deaminase [Enzymatic activity/volume] in Pleural fluid

0.00

0.0

1.4

—

11.4

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.0

1.4

—

(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence

0.00

0.0

1.0

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.0

1.0

—

(3025245) SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.3

—

(40766048) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.2

—

(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.6

—

(3001788) Aldosterone [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

198.2

—

(40760848) Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.4

—

(3027450) Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum

0.00

0.0

1.6

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.0

1.0

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.4

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

0.0

1.4

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

0.0

1.4

—

(3027008) Opiates [Presence] in Urine

0.00

0.0

1.0

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

(40759040) C peptide [Moles/volume] in Serum or Plasma --post meal

0.00

0.0

1.2

—

2.5

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

0.88

0.00

3.8

11.6

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

0.0

5.9

—

(40768806) Pleura Pathology biopsy report

0.00

0.0

2.4

—

(3022948) Iron [Moles/volume] in Serum or Plasma

0.97

0.00

2.0

2.8

9.3

11.6

umol/l

—

(3018171) Choriogonadotropin [Units/volume] in Serum or Plasma

0.00

0.0

1.0

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.0

1.2

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

0.00

0.0

1.2

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.4

—

(3012202) Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.4

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.8

—

(3017817) Protein [Mass] in Urine collected for unspecified duration

0.00

0.0

8.0

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.0

1.0

—

(3007368) IgG [Mass/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

49.8

—

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_LARYNX – Carcinoma in situ of larynx

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

≡ Risteys

FG R12 + FR

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Carcinoma in situ of larynx

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

All original rules

Similar endpoints

Case counts by codes

Upset plot

Case counts by code for Carcinoma in situ of larynx (CD2_INSITU_LARYNX)

Summary Statistics

-FinRegistry-

-FinnGen-

Key figures

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Relationships between endpoints